STARMED has entered a new growth phase marked by CE-MDR and MDSAP certifications, expanded FDA 510(k) approvals, and the establishment of STARMED America and STARMED (Sichuan) MedTech Co., Ltd., strengthening global market access and manufacturing.
Clinical adoption accelerated through participation in an NHS England fibroid ablation pilot and the official inclusion of thyroid RFA under U.S. CPT codes, enabling reimbursement-driven expansion. In 2025, STARMED advanced into multi-modality with the launch of STARwave, its microwave ablation system.
Supported by more than 600 peer-reviewed clinical publications, STARMED continues to expand across North America, Europe, the Middle East, Africa, and Latin America.
STARMED expanded regulatory approvals across Asia, the Middle East, and Eastern Europe, and formally entered the U.S. market. A manufacturing joint venture in China strengthened regional supply and scalability.
The portfolio broadened to include varicose vein ablation (VENISTAR) and surgical devices such as WELLCUT, reinforcing STARMED’s position as a diversified ablation specialist.
STARMED entered a global exclusive partnership with Taewoong Medical for pancreatic and biliary applications enabling STARMED to achieve rapid international growth.
Regulatory approval in Japan led to 35% market share in liver ablation within one year. The company expanded into the Middle East and Eastern Europe and entered the uterine fibroid treatment market.
Founded in 2009, STARMED developed the VIVA RF Generator and introduced the world’s first thyroid-dedicated RF electrode. Early MFDS and CE approvals enabled initial expansion into Europe and Asia including Italy, Austria, Singapore, and Taiwan.
Specialized electrodes for pancreatic (EUSRA) and biliary (ELRA) applications entered clinical practice, and STARMED’s core products were recognized as World-Class Products of Korea.
In 2002, Professor Jung Hwan Baek of Asan Medical Center in Seoul performed the world’s first thyroid radiofrequency ablation. In response, we drew upon its deep expertise in liver RFA to collaborate with Professor Baek to develop a dedicated thyroid electrode, laying the clinical and technological foundation for global adoption of thyroid RFA.
STARMED Co., Ltd. I Henry Shin
B-4th & 12th floor, Daebang Triplaon, 158, Haneulmaeul-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, 10355
Tel : +82 31 816 3546 I Fax : +82 31 816 4546
Email : inquiry@STARmed4u.com
copyright ⓒ STARmed Co., Ltd. All Rights Reserved.
STARMED Co., Ltd. I Henry Shin
(Jungsan-dong, Daebang-Triplaon Business Tower), B-dong, 4F & 12F, 158, Haneulmaeul-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10355, Korea
Tel : +82 31 816 3546 I Fax : +82 31 816 4546 I Email : inquiry@starmed4u.com
copyright ⓒ STARMED Co., Ltd. All Rights Reserved.
